Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2011 (2011), Article ID 368140, 12 pages
http://dx.doi.org/10.4061/2011/368140
Research Article

Long-Term Use of Aldosterone-Receptor Antagonists in Uncontrolled Hypertension: A Retrospective Analysis

1Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
2Department of Internal Medicine, TweeSteden Hospital, 5141 BM Waalwijk, The Netherlands

Received 30 September 2010; Accepted 24 January 2011

Academic Editor: Alan Gradman

Copyright © 2011 Pieter M. Jansen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. I. Ogilvie, K. M. Piafsky, and J. Ruedy, “Antihypertensive responses to spironolactone in normal renin hypertension,” Clinical Pharmacology and Therapeutics, vol. 24, no. 5, pp. 525–530, 1978. View at Google Scholar · View at Scopus
  2. B. E. Karlberg, B. Kagedal, L. Tegler, K. Tolagen, and B. Bergman, “Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity,” The American Journal of Cardiology, vol. 37, no. 4, pp. 642–649, 1976. View at Google Scholar · View at Scopus
  3. J. H. Kreeft, P. Larochelle, and R. I. Ogilvie, “Comparison of chlorthalidone and spironolactone in low-renin essential hypertension,” Canadian Medical Association Journal, vol. 128, no. 1, pp. 31–34, 1983. View at Google Scholar · View at Scopus
  4. M. H. Weinberger, B. Roniker, S. L. Krause, and R. J. Weiss, “Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension,” American Journal of Hypertension, vol. 15, no. 8, pp. 709–716, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. H. Weinberger, W. B. White, L. M. Ruilope et al., “Effects of eplerenone versus losartan in patients with low-renin hypertension,” American Heart Journal, vol. 150, no. 3, pp. 426–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. E. D. Burgess, Y. Lacourcière, L. M. Ruilope-Urioste et al., “Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension,” Clinical Therapeutics, vol. 25, no. 9, pp. 2388–2404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. W. B. White, A. A. Carr, S. Krause, R. Jordan, B. Roniker, and W. Oigman, “Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension,” American Journal of Cardiology, vol. 92, no. 1, pp. 38–42, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Flack, S. Oparil, J. H. Pratt et al., “Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients,” Journal of the American College of Cardiology, vol. 41, no. 7, pp. 1148–1155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. G. H. Williams, E. Burgess, R. E. Kolloch et al., “Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension,” American Journal of Cardiology, vol. 93, no. 8, pp. 990–996, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. W. B. White, D. Duprez, R. S. Hillaire et al., “Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension,” Hypertension, vol. 41, no. 5, pp. 1021–1026, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Pitt, N. Reichek, R. Willenbrock et al., “Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study,” Circulation, vol. 108, no. 15, pp. 1831–1838, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. P. M. Jansen, F. Boomsma, A. H. van den Meiracker et al., “Aldosterone-to-renin ratio as a screening test for primary aldosteronism: the Dutch ARRAT study,” Netherlands Journal of Medicine, vol. 66, no. 5, pp. 220–228, 2008. View at Google Scholar · View at Scopus
  13. M. Sartori, L. A. Calò, V. Mascagna et al., “Aldosterone and refractory hypertension: a prospective cohort study,” American Journal of Hypertension, vol. 19, no. 4, pp. 373–379, 2006, discussion 380. View at Publisher · View at Google Scholar
  14. J. Staessen, P. Lijnen, and R. Fagard, “Rise in plasma concentration of aldosterone during long-term angiotensin II suppression,” Journal of Endocrinology, vol. 91, no. 3, pp. 457–465, 1981. View at Google Scholar · View at Scopus
  15. K. J. Schjoedt, S. Andersen, P. Rossing, L. Tarnow, and H. H. Parving, “Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate,” Diabetologia, vol. 47, no. 11, pp. 1936–1939, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. S. Bomback and P. J. Klemmer, “The incidence and implications of aldosterone breakthrough,” Nature Clinical Practice Nephrology, vol. 3, no. 9, pp. 486–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. K. Nishizaka, M. A. Zaman, and D. A. Calhoun, “Efficacy of low-dose spironolactone in subjects with resistant hypertension,” American Journal of Hypertension, vol. 16, no. 11, part 1, pp. 925–930, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Ouzan, C. Pérault, A. M. Lincoff, E. Carré, and M. Mertes, “The role of spironolactone in the treatment of patients with refractory hypertension,” American Journal of Hypertension, vol. 15, no. 4, part 1, pp. 333–339, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Sharabi, E. Adler, A. Shamis, N. Nussinovitch, A. Markovitz, and E. Grossman, “Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension,” American Journal of Hypertension, vol. 19, no. 7, pp. 750–755, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. A. Lane, S. Shah, and D. G. Beevers, “Low-dose spironolactone in the management of resistant hypertension: a surveillance study,” Journal of Hypertension, vol. 25, no. 4, pp. 891–894, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Chapman, J. Dobson, S. Wilson et al., “Effect of spironolactone on blood pressure in subjects with resistant hypertension,” Hypertension, vol. 49, no. 4, pp. 839–845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. de Souza, E. Muxfeldt, R. Fiszman, and G. Salles, “Efficacy of spironolactone therapy in patients with true resistant hypertension,” Hypertension, vol. 55, no. 1, pp. 147–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Rodilla, J. A. Costa, F. Pérez-Lahiguera, E. Baldó, C. González, and J. M. Pascual, “Spironolactone and doxazosin treatment in patients with resistant hypertension,” Revista Espanola de Cardiologia, vol. 62, no. 2, pp. 158–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Saha, G. J. Eckert, W. T. Ambrosius et al., “Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension,” Hypertension, vol. 46, no. 3, pp. 481–487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Mahmud, M. Mahgoub, M. Hall, and J. Feely, “Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?” American Journal of Hypertension, vol. 18, no. 12, pp. 1631–1635, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. L. M. Prisant, H. Krum, B. Roniker, S. L. Krause, K. Fakouhi, and W. He, “Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?” Journal of Clinical Pharmacology, vol. 43, no. 11, pp. 1203–1210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. WHO Collaborating Centre for Drug Statistics Methodology, “ATC/DDD Index 2010,” http://www.whocc.no/atc_ddd_index/.
  28. P. Mulatero, F. Rabbia, A. Milan et al., “Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism,” Hypertension, vol. 40, no. 6, pp. 897–902, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. P. M. Jansen, A. H. J. Danser, B. P. Imholz, and A. H. van den Meiracker, “Aldosterone-receptor antagonism in hypertension,” Journal of Hypertension, vol. 27, no. 4, pp. 680–691, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. J. Hood, K. P. Taylor, M. J. Ashby, and M. J. Brown, “The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio,” Circulation, vol. 116, no. 3, pp. 268–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Pimenta, K. K. Gaddam, S. Oparil et al., “Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial,” Hypertension, vol. 54, no. 3, pp. 475–481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Jeunemaitre, G. Chatellier, C. Kreft-Jais et al., “Efficacy and tolerance of spironolactone in essential hypertension,” American Journal of Cardiology, vol. 60, no. 10, pp. 820–825, 1987. View at Google Scholar · View at Scopus
  33. K. P. Tamirisa, K. D. Aaronson, and T. M. Koelling, “Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure,” American Heart Journal, vol. 148, no. 6, pp. 971–978, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Khosla, R. Kalaitzidis, and G. L. Bakris, “Predictors of hyperkalemia risk following hypertension control with aldosterone blockade,” American Journal of Nephrology, vol. 30, no. 5, pp. 418–424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. J. W. Funder, R. M. Carey, C. Fardella et al., “Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 9, pp. 3266–3281, 2008. View at Publisher · View at Google Scholar · View at Scopus